Abstract
Hepatocyte growth factor receptor, more commonly referred to as MET, is a known oncogenic driver in multiple malignancies. Recently the tyrosine kinase inhibitors capmatinib and tepotinib have been approved by the United States Food and Drug Administration for the treatment of patients with non-small cell lung cancers that harbor MET exon 14 skipping mutations. Mutations that affect the donor or acceptor splice sites of MET exon 14 pre-mRNA can lead to skipping of exon 14 during splicing and an mRNA product where exons 13 and 15 are fused.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
